Company / Capital Expenditures
Immuneering Corp Capital Expenditures History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$742.5K
FY2023
5-year range
$53.4K / $742.5K
FY2021-FY2023
Trend
+1121.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +1121% YoY in FY2023, a notable deviation from the 2-year average annual change of +568%.
Based on SEC 10-K filings.
$742,483 in FY2023.
Improved from $53,415 to $742,483 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, capital expenditures increased 1121.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $742.5K | +1121.5% |
| FY2022 | $60.8K | +13.8% |
| FY2021 | $53.4K | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026